Bariatric Surgery: An Overview of Methods, Real Outcomes, and Risks

Bariatric surgery is still sometimes framed as an "easy way out" for people who couldn't lose weight on their own. That framing conflicts with what's known about the physiology of obesity: after substantial weight loss, the body defends against regaining it through lasting hormonal changes — a drop in leptin, a rise in ghrelin, and a slower resting metabolism — that make maintaining the loss difficult for years, regardless of a patient's willpower. That's one reason diet-only interventions rarely produce a durable long-term effect in people with class III obesity.

Bariatric surgery (more precisely, metabolic surgery, since its effects go far beyond mechanically shrinking the stomach) is currently the most effective available intervention for severe obesity and its metabolic complications. It's generally offered to people with a BMI of 40 kg/m² or higher, or 35 kg/m² or higher with coexisting complications such as type 2 diabetes, hypertension, or obstructive sleep apnea — though some scientific societies now recommend lower BMI thresholds when type 2 diabetes is present, especially in Asian populations.

Sleeve gastrectomy (SG) surgically removes roughly 75-80% of the stomach along its greater curvature, leaving a narrow "sleeve" structure. It limits stomach capacity, but just as important, it removes the part of the stomach that produces ghrelin, the hormone that stimulates appetite — which partly explains why the effect isn't just mechanical "less room for food."

Roux-en-Y gastric bypass (RYGB) is a more complex procedure: the surgeon creates a small stomach pouch and connects it directly to the middle portion of the small intestine, bypassing most of the stomach, the duodenum, and the initial segment of the jejunum. Beyond limiting meal volume, it also changes digestion and nutrient absorption and significantly affects gut hormone secretion (including GLP-1 and PYY) in ways that promote satiety — a mechanism that partly overlaps with GLP-1 receptor agonist drugs, discussed later in this article.

This is the first long-term (5+ year) randomized trial showing standard RYGB to be superior to SG specifically in type 2 diabetes remission — earlier data came mostly from observational studies, which risk patients referred to the more complex procedure (RYGB) systematically differing from those referred to SG. Randomization eliminates that problem, making this result more reliable.

Perioperative mortality (within 30 days of surgery) at modern bariatric centers is low — around 0.08% for primary procedures, according to large pooled analyses covering more than a million procedures. That's comparable to many routine surgical procedures, though obviously not zero, which is worth keeping in mind when weighing benefit against risk.

With the rise of semaglutide and tirzepatide, it's natural to ask whether these drugs could replace bariatric surgery for some patients. Data from studies directly comparing the two interventions currently show a clear advantage for surgery in the scale of weight loss achieved, though the difference in safety profile and invasiveness favors the drugs.

Qualification for bariatric surgery at a responsible center isn't limited to measuring BMI. It typically involves evaluation by a multidisciplinary team — a bariatric surgeon, an endocrinologist or internist, a clinical dietitian, and a psychologist or psychiatrist — whose job is to assess a patient's readiness for lasting dietary change, rule out untreated eating disorders or unmanaged mental illness that could complicate recovery, and educate the patient about what life after surgery actually requires.

Most programs also require documented prior attempts at nonsurgical weight loss and, at many centers, a several-month preparation period involving dietary changes, cardiac and pulmonary evaluation (including for sleep apnea), and in some cases preoperative weight loss to reduce surgical risk, particularly liver volume that can complicate surgical access.

Bariatric surgery remains the most effective available intervention for severe obesity — randomized trial data show not just large, durable weight loss but a real reduction in mortality and major cardiovascular complications. It's nonetheless a major decision, requiring lasting lifestyle change, lifelong supplementation, and acceptance of real, though at experienced centers small, surgical risk.

The arrival of effective GLP-1 drugs hasn't replaced surgery, but it has expanded the range of options — for some patients, pharmacotherapy will be the right first step; for others, surgery will remain the only intervention capable of producing an effect large enough to reverse serious metabolic complications. The choice between sleeve and bypass, like the choice between surgery and pharmacotherapy, should always be an individual decision made together with a specialist team, not a choice of the "better" option in the abstract.